Search

everythinglearnresearchcommunity

for

Search:↓

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

Using a topical formula with 5% minoxidil and 0.01% retinoic acid is considered effective, as tretinoin can enhance minoxidil results and improve scalp health.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The user started a hair care routine using 0.5mg finasteride daily, 2ml of 5% minoxidil, and 4.5mg of cetirizine topically to address hair loss. They plan to provide updates and are also interested in cetirizine's potential to reduce scalp itching and redness due to its anti-inflammatory properties.

A person had a successful hair transplant in Turkey with 3200 grafts using FUE and DHI techniques, and is satisfied with the results after 9 months. They have been using finasteride for 7 years to maintain hair health.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation discusses using topical taurine for hair loss, with one user reporting minimal shedding but no regrowth after 10 months. Minoxidil and finasteride are mentioned as common treatments.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

A user shared that taking vitamin E, specifically tocotrienols, seemed to reduce their hair shedding, and they are also using finasteride, minoxidil, and derma rolling for hair loss. Another user cautioned against high doses of vitamin E due to potential health risks.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The user is experiencing hair loss without a family history and suspects stress or telogen effluvium (TE) as the cause, despite using finasteride without results. Others suggest stress, vitamin deficiencies, or other conditions could be factors, and some mention that balding can occur without a family history.

A trans woman is curious about the impact of HRT on hair regrowth and scalp tension. Her current regimen includes finasteride, spironolactone, estradiol, ketoconazole, vitamin D, iron, and plans to add oral minoxidil and restart derma rolling.

The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation is about finding reputable clinics in Canada or near the US border that offer DUT mesotherapy for hair loss. The user is seeking recommendations and cost information for these treatments.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The conversation is about finding a foam product that combines minoxidil and tretinoin for hair loss treatment. The user is seeking purchasing options for this specific combination.

A user is considering a solution with 7% minoxidil, 0.25% finasteride, and 0.0125% tretinoin for hair loss, as suggested by their dermatologist. Other users share their experiences with similar treatments, noting mixed results and suggesting stronger alternatives like dutasteride.